Praxis Precision Medicines 报告了乌利沙考胺治疗特发性震颤的积极 3 期试验结果，将于 2025 年 10 月 16 日将库存提高 100% 以上。 Praxis Precision Medicines reports positive Phase 3 trial results for ulixacaltamide in treating essential tremor, boosting stock over 100% on October 16, 2025.

Praxis Precision Medicines 报告称，乌柳沙考胺治疗特发性震颤的 3 期 Essential3 试验取得了积极的顶线结果，显示八周后日常功能改善了 4.3 分。 Praxis Precision Medicines reported positive topline results from its Phase 3 Essential3 trials for ulixacaltamide in treating essential tremor, showing a 4.3-point improvement in daily functioning after eight weeks. 2025年10月16日, 市场前交易的库存激增超过100%。 The drug demonstrated sustained effectiveness, prompting a more than 100% stock surge in pre-market trading on October 16, 2025. 该公司计划寻求与林业发展局举行NDA前会议,并打算在2026年初提交新的药物申请。 The company plans to seek a pre-NDA meeting with the FDA and aims to submit a New Drug Application by early 2026.